NIH Clinical Trials: How They Work and How to Participate

NIH-sponsored clinical trials represent one of the largest structured networks of human subjects research in the United States, operating across the NIH Clinical Center and hundreds of affiliated sites nationwide. This page explains how those trials are designed, regulated, and executed — and details the formal steps by which eligible individuals enter a trial. Understanding the mechanics and classification framework helps patients, caregivers, and researchers navigate a process that is governed by federal statute, institutional review requirements, and phase-specific safety protocols.

• Definition and scope
• Core mechanics or structure
• Causal relationships or drivers
• Classification boundaries
• Tradeoffs and tensions
• Common misconceptions
• Checklist or steps (non-advisory)
• Reference table or matrix

Definition and scope

A clinical trial, as defined by the National Institutes of Health, is a prospective biomedical or behavioral research study of human participants designed to answer specific questions about biomedical or behavioral interventions (NIH Definition of a Clinical Trial). The NIH definition — formalized through policy updates effective January 25, 2018 — distinguishes clinical trials from observational studies by the presence of an intervention and the prospective assignment of participants to conditions.

NIH funds and conducts clinical trials through two parallel tracks. Intramural trials are conducted directly at the NIH campus in Bethesda, Maryland, primarily at the NIH Clinical Center (Building 10), which operates as a 200-bed research hospital dedicated exclusively to clinical investigation. Extramural trials are funded through NIH grants and cooperative agreements at universities, hospitals, and research centers across all 50 states. The NIH intramural vs. extramural research distinction shapes who sponsors a trial, who controls the protocol, and what oversight structures apply.

As of the ClinicalTrials.gov registry, more than 470,000 studies have been registered globally, with a substantial portion carrying NIH or NIH-affiliated funding designations (ClinicalTrials.gov). Federal regulations at 45 CFR 46 (the Common Rule) and 21 CFR Parts 50 and 56 (FDA regulations) jointly govern the conduct of clinical trials involving human subjects.

Core mechanics or structure

Every NIH clinical trial operates under a formal protocol — a document specifying the study's objectives, design, methodology, statistical considerations, and conditions for participant eligibility. The protocol is reviewed and approved by an Institutional Review Board (IRB) before enrollment begins, a requirement under 45 CFR 46.109.

Trials progress through four sequential phases, each with a distinct safety and efficacy mandate:

• Phase I: Tests a new intervention in a small group (typically 20–80 participants) to evaluate safety, determine a safe dosage range, and identify side effects.
• Phase II: Expands the participant pool (typically 100–300) to assess preliminary efficacy and further evaluate safety.
• Phase III: Large-scale testing (typically 1,000–3,000 or more participants) comparing the intervention against the current standard of care or a placebo, generating the statistical power required for regulatory approval.
• Phase IV: Post-market surveillance studies conducted after an intervention receives regulatory approval, monitoring long-term effects in diverse real-world populations.

Randomized controlled trials (RCTs), the methodological gold standard, assign participants randomly to intervention or control arms using allocation algorithms that prevent investigator bias. Blinding — single-blind (participant unaware), double-blind (both participant and investigator unaware), or open-label — is specified in the protocol based on feasibility and scientific necessity.

All NIH-funded clinical trials with at least one site in the United States must register on ClinicalTrials.gov and submit results within 12 months of the primary completion date, per the Final Rule implementing 42 CFR Part 11, published September 16, 2016.

Causal relationships or drivers

Several regulatory and scientific drivers explain the structure of NIH clinical trial requirements. The 1974 National Research Act — passed in the wake of the Tuskegee Syphilis Study — created the National Commission for the Protection of Human Subjects and led directly to the Belmont Report (1979), which established the ethical principles of respect for persons, beneficence, and justice that underpin all IRB review.

The NIH Revitalization Act of 1993 mandated the inclusion of women and minorities in NIH-funded clinical research, responding to documented gaps in demographic representation that had produced findings of uncertain generalizability. NIH's policy on inclusion of individuals across the lifespan, updated in 2019, extended those requirements to pediatric populations.

Data safety monitoring boards (DSMBs) are required for Phase III trials and any trial with mortality or major morbidity as an endpoint. DSMBs provide independent interim analysis, with authority to recommend early termination if evidence of harm, futility, or overwhelming efficacy meets pre-specified stopping rules. This mechanism exists because the primary investigator carries an inherent conflict of interest in evaluating whether their own trial should continue.

The NIH human subjects research protections framework ties together these regulatory layers into a coherent oversight structure.

Classification boundaries

NIH classifies clinical trials along two axes: by study type and by funding mechanism.

By study type, trials fall into four categories as defined by ClinicalTrials.gov:
1. Interventional (clinical trial): A study assigning participants to receive specific interventions.
2. Observational: Participants are observed without assignment to an intervention.
3. Expanded access: Use of an investigational drug or device outside a controlled trial for patients with serious conditions.
4. Patient registry: Collects standardized information about a disease or condition over time.

By funding mechanism, NIH distinguishes:
- Cooperative agreements (U-series): NIH staff maintains substantial programmatic involvement.
- Research grants (R-series): The grantee institution conducts the trial with NIH providing funding but not direct operational involvement.
- Contracts: NIH defines the research question and retains control over deliverables.

The boundary between a clinical trial and a clinical study carrying only minimal risk has significant regulatory consequences. Studies meeting the NIH definition of a clinical trial trigger requirements for Good Clinical Practice (GCP) training of investigators, DSMB consideration, and mandatory ClinicalTrials.gov registration — requirements that do not apply to observational studies. A detailed breakdown of NIH grant types and mechanisms covers how these funding categories interact with trial design obligations.

Tradeoffs and tensions

Placebo controls raise the most persistent ethical tension in trial design. The Declaration of Helsinki (World Medical Association, 2013 revision) states that placebos may be used only when no proven intervention exists or when compelling methodological reasons require it and patients will not suffer serious harm. NIH investigators designing trials for conditions with existing standard-of-care treatments must justify placebo use explicitly in the protocol and obtain specific IRB approval.

Adaptive trial designs — which allow pre-specified modifications to sample size, randomization ratios, or endpoint selection based on interim data — accelerate drug development timelines but introduce analytic complexity. The FDA's 2019 guidance on adaptive designs acknowledges their value while cautioning that unplanned adaptations can inflate Type I error rates.

Access equity creates a structural tension. Highly restrictive eligibility criteria improve internal validity by reducing confounding variables but limit generalizability to real-world populations. NIH's 2017 Policy for the Dissemination of NIH-Funded Clinical Trial Information and the broader NIH data sharing policy attempt to address downstream equity in research outputs, but enrollment disparities persist at the trial entry point.

Compensation for participation raises concerns about undue inducement, particularly in Phase I trials where there is no expected therapeutic benefit. IRBs evaluate whether payment levels are coercive, a judgment that remains inherently subjective and varies across institutions.

Common misconceptions

Misconception: Participation in a clinical trial guarantees access to the experimental treatment.
Correction: Participants in randomized controlled trials may be assigned to the control arm, which may receive a placebo or the existing standard of care. Assignment is random; no guarantee of receiving the experimental intervention exists.

Misconception: NIH pays all costs associated with trial participation.
Correction: Costs covered vary by trial. Intramural trials at the NIH Clinical Center do cover inpatient care, study-related tests, and travel reimbursement for enrolled participants. Extramural trials may bill routine care costs to insurance, cover only study-related procedures, or provide stipends — terms that differ by individual protocol.

Misconception: Clinical trials are a last resort for patients who have exhausted all other options.
Correction: Phase I trials typically do enroll patients with advanced disease who have failed standard treatments, but Phase II, III, and IV trials routinely enroll patients at earlier stages of disease or even healthy volunteers. Eligibility is protocol-specific.

Misconception: Withdrawing from a trial has negative consequences.
Correction: 45 CFR 46.116(b)(8) requires that participants be informed they may discontinue participation at any time without penalty or loss of benefits to which they are otherwise entitled. Withdrawal is a legal right, not a forfeiture event.

Checklist or steps (non-advisory)

The following sequence describes the standard pathway by which an individual enters an NIH clinical trial:

1. Identify candidate trials — Search ClinicalTrials.gov using condition, location, age, and phase filters. The NIH health information for patients portal also lists NIH Clinical Center open protocols.
2. Review eligibility criteria — Each trial lists inclusion criteria (requirements that must be met) and exclusion criteria (factors that disqualify participation). Both are published in the trial's ClinicalTrials.gov record.
3. Contact the research team — A contact name, phone number, or email is listed in each ClinicalTrials.gov record under "Contacts and Locations." Initial contact does not constitute enrollment.
4. Undergo screening — The research team conducts a medical history review and may require diagnostic tests, lab work, or imaging to confirm eligibility. Screening is distinct from enrollment.
5. Receive informed consent — The principal investigator or a designated team member explains the study purpose, procedures, risks, benefits, and alternatives. Participants sign an IRB-approved informed consent document. This step is required under 45 CFR 46.116 before any study procedures begin.
6. Complete baseline assessments — Enrolled participants undergo initial measurements that establish a pre-intervention baseline for all primary and secondary endpoints.
7. Begin study procedures — Participants follow the assigned protocol arm, which may include drug administration, behavioral interventions, device use, or observation-only schedules.
8. Attend follow-up visits — Protocols specify follow-up intervals for safety monitoring, efficacy assessment, and adverse event reporting.
9. Receive end-of-study summary — NIH policy requires that trial results be reported to ClinicalTrials.gov and, where applicable, communicated to participants.

Reference table or matrix

NIH Clinical Trial Phases: Key Parameters

Regulatory Frameworks Governing NIH Clinical Trials

The broader scope of NIH research infrastructure — including how the NIH organizational structure distributes trial oversight authority across institutes and centers — provides additional context for understanding which institute sponsors, funds, and monitors any given trial. For an overview of the full range of NIH research activity, the home page provides orientation to the agency's programs and reference resources.